Skip to content
Delayed ~15 min

ELDN ELEDON PHARMACEUTICALS INC

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: Fri 13 Nov 2026 · estimated

What 9 analyst firms say about ELEDON PHARMACEUTICALS INC: their latest ratings, price targets and how far the stock is from them. How it works

2.61 USD+0.15 (+5.89%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+264.7%to the avg target 9.50 USD+6.90 USD
Buy 7 · Hold 1 · Sell 0

8 rated views · 9 analyst/firm records · 9 firms

Latest report4 Sep 2026avg report date 2 Jul
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
  • Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD

Recent analyst activity · last 90 days

Our tracked history has 3 reports on ELDN from 3 analyst firms in the last 90 days (9 firms in the past year).

Comparing each firm's latest target with its previous one: 1 left it unchanged and 1 has its first observed target in the past year.

No firm's latest available rating differs from its previous one.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
Cantor FitzgeraldPete StavropoulosBuy23 Mar 2026—
Craig-HallumAlbert LoweBuy16 Mar 202612.00 USD
GuggenheimVamil DivanBuy14 Aug 20268.00 USD
Leerink PartnersThomas J SmithBuy22 Jun 20267.00 USD
Lifesci CapitalRami KatkhudaBuy22 Jun 20268.00 USD
Noble Capital MarketsRobert LeboyerBuy4 Sep 202610.00 USD
Rodman & RenshawSeema SheoranBuy21 Jul 202612.00 USD
Weiss RatingsUnnamed analyst—21 Sep 2026—
Data feed RESEARCHResearch TeamHold15 Jun 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 03:25 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.